The Non-interventional BonViva Intravenous Versus Alendronate (VIVA) Study: Real-world Adherence and Persistence to Medication, Efficacy, and Safety, in Patients with Postmenopausal Osteoporosis

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2013 Oct 5

PMID 24091594

Citations 12

Authors

P Hadji

D Felsenberg

M Amling

L C Hofbauer

J A Kandenwein

A Kurth

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Adherence and persistence to oral bisphosphonates in women with postmenopausal osteoporosis is suboptimal. In this study, patients were treated with either oral or intravenous bisphosphonates. The increased adherence and persistence observed in patients receiving intravenous medication compared with those receiving oral medication may improve health outcomes.

Introduction: Poor adherence and persistence to oral medication are often observed in women with postmenopausal osteoporosis (PMO). The purpose of the non-interventional BonViva Intravenous Versus Alendronate (VIVA) study was to determine whether, in a real-world setting, (1) increased adherence and persistence to medication would be observed in women with PMO receiving intravenous (i.v.) ibandronate versus oral alendronate, (2) a correlation exists between adherence and persistence to medication and drug efficacy, and (3) any unexpected adverse events/serious adverse events (AEs/SAEs) may occur.

Methods: The study was conducted in 632 centers in Germany. A total of 6,064 females with PMO were enrolled and recruited into one of two treatment arms: quarterly i.v. administration of 3 mg ibandronate or weekly oral medication of 70 mg alendronate, for 12 months. At the end of the study, adherence and persistence to medication, new osteoporotic fractures, mobility, use of analgesics, and AEs/SAEs were determined.

Results: Greater adherence and persistence to medication were observed in the ibandronate treatment arm compared with the alendronate treatment arm. Although there was no significant difference in the number of patients with new vertebral, hip, or forearm fractures between treatment arms, a significantly greater increase in mobility and decrease in the use of analgesics were reported in the ibandronate treatment arm. No unexpected AEs/SAEs occurred in either arm.

Conclusions: Adherence and persistence to medication were greater in women with PMO receiving i.v. ibandronate compared with those receiving oral alendronate. This may have led to an increase in mobility and a decrease in pain in these patients.

Citing Articles

[Update of the S3-guideline on diagnostics, prophylaxis and treatment of osteoporosis].

Drey M, Otto S, Thomasius F, Schmidmaier R Orthopadie (Heidelb). 2024; 53(7):541-549.

PMID: 38806800 DOI: 10.1007/s00132-024-04522-6.

[Update of the S3-guideline on diagnostics, prophylaxis and treatment of osteoporosis].

Drey M, Otto S, Thomasius F, Schmidmaier R Z Gerontol Geriatr. 2023; 56(7):597-605.

PMID: 37843610 DOI: 10.1007/s00391-023-02245-5.

Evaluation of pain, quality of life, and patient satisfaction in parenterally treated patients with postmenopausal osteoporosis.

Ozsoy-Unubol T, Akyuz G, Mirzayeva S, Guler T Turk J Phys Med Rehabil. 2020; 66(3):262-270.

PMID: 33089082 PMC: 7557633. DOI: 10.5606/tftrd.2020.4114.

Factors affecting continuation of weekly teriparatide administration in rural areas.

Tsuchie H, Miyakoshi N, Kasukawa Y, Abe H, Masutani N, Shimada Y J Bone Miner Metab. 2019; 38(2):248-253.

PMID: 31583539 DOI: 10.1007/s00774-019-01051-7.

Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study.

Tanaka M, Nakamura Y, Itoh S, Kato Y Osteoporos Sarcopenia. 2019; 3(1):37-44.

PMID: 30775501 PMC: 6372817. DOI: 10.1016/j.afos.2016.12.002.

References

Prieto-Alhambra D, Nogues X, Javaid M, Wyman A, Arden N, Azagra R . An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW). Ann Rheum Dis. 2012; 72(6):911-7. PMC: 4886333. DOI: 10.1136/annrheumdis-2012-201451. View

Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc R, Mahoney P . Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone. 2004; 34(5):881-9. DOI: 10.1016/j.bone.2004.01.007. View

Hamilton B, McCoy K, Taggart H . Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003; 14(3):259-62. DOI: 10.1007/s00198-002-1370-3. View

Harris S, Watts N, Genant H, McKeever C, Hangartner T, Keller M . Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282(14):1344-52. DOI: 10.1001/jama.282.14.1344. View

Hoer A, Seidlitz C, Gothe H, Schiffhorst G, Olson M, Hadji P . Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence. 2009; 3:25-30. PMC: 2778431. View

Silverman S, Schousboe J, Gold D . Oral bisphosphonate compliance and persistence: a matter of choice?. Osteoporos Int. 2010; 22(1):21-6. PMC: 3017316. DOI: 10.1007/s00198-010-1274-6. View

Delmas P, Adami S, Strugala C, Stakkestad J, Reginster J, Felsenberg D . Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006; 54(6):1838-46. DOI: 10.1002/art.21918. View

Curtis J, Xi J, Westfall A, Cheng H, Lyles K, Saag K . Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care. 2009; 47(3):334-41. PMC: 2693955. DOI: 10.1097/MLR.0b013e31818afa1c. View

Hooven F, Adachi J, Adami S, Boonen S, Compston J, Cooper C . The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int. 2009; 20(7):1107-16. PMC: 2690851. DOI: 10.1007/s00198-009-0958-2. View

10.

Ziller V, Kostev K, Kyvernitakis I, Boeckhoff J, Hadji P . Persistence and compliance of medications used in the treatment of osteoporosis--analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther. 2012; 50(5):315-22. DOI: 10.5414/cp201632. View

11.

Vrijens B, de Geest S, Hughes D, Przemyslaw K, Demonceau J, Ruppar T . A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73(5):691-705. PMC: 3403197. DOI: 10.1111/j.1365-2125.2012.04167.x. View

12.

Tosteson A, Grove M, Hammond C, Moncur M, Ray G, Hebert G . Early discontinuation of treatment for osteoporosis. Am J Med. 2003; 115(3):209-16. DOI: 10.1016/s0002-9343(03)00362-0. View

13.

Simon J, Lewiecki E, Smith M, Petruschke R, Wang L, Palmisano J . Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther. 2002; 24(11):1871-86. DOI: 10.1016/s0149-2918(02)80085-6. View

14.

Feldstein A, Weycker D, Nichols G, Oster G, Rosales G, Boardman D . Effectiveness of bisphosphonate therapy in a community setting. Bone. 2008; 44(1):153-9. DOI: 10.1016/j.bone.2008.09.006. View

15.

Sambrook P, Cooper C . Osteoporosis. Lancet. 2006; 367(9527):2010-8. DOI: 10.1016/S0140-6736(06)68891-0. View

16.

Rizzoli R . Bisphosphonates for post-menopausal osteoporosis: are they all the same?. QJM. 2011; 104(4):281-300. DOI: 10.1093/qjmed/hcq259. View

17.

Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T . GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2011; 23(1):223-31. DOI: 10.1007/s00198-011-1535-z. View

18.

Thiebaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann J . Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med. 1997; 103(4):298-307. DOI: 10.1016/s0002-9343(97)00249-0. View

19.

Siris E, Selby P, Saag K, Borgstrom F, Herings R, Silverman S . Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009; 122(2 Suppl):S3-13. DOI: 10.1016/j.amjmed.2008.12.002. View

20.

Gold D, Martin B, Frytak J, Amonkar M, Cosman F . A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin. 2007; 23(3):585-94. DOI: 10.1185/030079906X167615. View